US panel votes to keep Advair and Symbicort for asthma
This article was originally published in Scrip
Executive Summary
Long-acting beta-2 adrenergic agonist (LABA) combination products should continue to be used for asthma, but the single-agent LABAs salmeterol and formoterol should be stripped of their current indications because of increased risks of asthma-related death and exacerbations with monotherapy, the US FDA's outside experts recommended on December 11th.